Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan

INTRODUCTION: Real-world data regarding the impact of hepatic fibrosis on the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) treatment is limited in the Asian population. METHODS: We analyzed data for all 823 patients with hepatitis C virus treated with SOF/VEL from June 2019 to September 2020 at...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yu-Ting, Hsieh, Yung-Yu, Chen, Wei-Ming, Tung, Shui-Yi, Wei, Kuo-Liang, Shen, Chen-Heng, Chang, Kao-Chi, Lu, Chung-Kuang, Yen, Chih-Wei, Lu, Sheng-Nan, Hung, Chao-Hung, Chang, Te-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199354/
https://www.ncbi.nlm.nih.gov/pubmed/34118889
http://dx.doi.org/10.1186/s12876-021-01837-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199354/
https://www.ncbi.nlm.nih.gov/pubmed/34118889
http://dx.doi.org/10.1186/s12876-021-01837-y

Ejemplares similares